

LEGISLATIVE BUDGET BOARD
Austin, Texas

FISCAL NOTE, 86TH LEGISLATIVE REGULAR SESSION

April 27, 2019

TO: Honorable Senfronia Thompson, Chair, House Committee on Public Health

FROM: John McGeady, Assistant Director Sarah Keyton, Assistant Director
Legislative Budget Board

IN RE: **HB3148** by Parker (Relating to the administration and oversight of investigational adult stem cell treatments administered to certain patients.), **Committee Report 1st House, Substituted**

No significant fiscal implication to the State is anticipated.

The bill would require that institutional review boards that oversee investigational stem cell treatments either be affiliated with a medical school, affiliated with a hospital, accredited by the Association for the Accreditation of Human Research Protection programs, registered by the United States Department of Health and Human Services, or accredited by another national accreditation organization acceptable to the Department of State Health Services (DSHS).

The bill would also prohibit a government entity from considering an adult stem cell product to be an adulterated or misbranded drug solely on the basis of the drug not being approved by United States Food and Drug Administration.

DSHS, the Health and Human Services Commission, and the Texas Medical Board indicate that the provisions of the bill could be absorbed using existing resources.

Local Government Impact

No significant fiscal implication to units of local government is anticipated.

Source Agencies: 503 Texas Medical Board, 529 Health and Human Services Commission,
537 State Health Services, Department of

LBB Staff: WP, AKi, JQ, BH